1. Home
  2. MFIN vs TLSI Comparison

MFIN vs TLSI Comparison

Compare MFIN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medallion Financial Corp.

MFIN

Medallion Financial Corp.

N/A

Current Price

$9.47

Market Cap

273.7M

Sector

Finance

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$2.40

Market Cap

250.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MFIN
TLSI
Founded
1995
2010
Country
United States
United States
Employees
179
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.7M
250.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MFIN
TLSI
Price
$9.47
$2.40
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
★ $11.25
$7.75
AVG Volume (30 Days)
52.3K
★ 247.4K
Earning Date
10-29-2026
11-10-2026
Dividend Yield
★ 6.00%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
N/A
$12.34
Revenue Next Year
$12.27
$29.38
P/E Ratio
$6.21
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$7.85
$2.20
52 Week High
$12.26
$7.95

Technical Indicators

Market Signals
Indicator
MFIN
TLSI
Relative Strength Index (RSI) 31.44 25.64
Support Level $9.30 $2.20
Resistance Level $10.10 $4.35
Average True Range (ATR) 0.46 0.34
MACD -0.11 -0.12
Stochastic Oscillator 15.34 6.43

Price Performance

Historical Comparison
MFIN
TLSI

About MFIN Medallion Financial Corp.

Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: